New chief exec to lead ambitious growth plans at ITM Isotope

20 June 2024
radiotherapy_radioisotope_production_manufacturing_big

Munich, Germany-based radiopharmaceutical company ITM Isotope Technologies has appointed Andrew Cavey as its new chief executive officer.

From the start of September, Dr Cavey will take over from current CEO, Steffen Schuster, who will join ITM's supervisory board.

Dr Cavey brings experience from his roles at Bristol Myers Squibb (NYSE: BMY) and Novartis (NOVN: VX). At Bristol Myers he served as a senior vice president as the company made its entry into radiopharmaceuticals.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical